Sale of Zohydro ER business - Income Statement and Balance Sheet Disclosures Related to Zohydro (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
Disposal Group, Including Discontinued Operation, Balance Sheet Disclosures [Abstract]
Total current assets of discontinued operations	$ 6,636		$ 7,196
Total current liabilities of discontinued operations	21,397		22,307
Zohydro ER
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Net product revenue	5,006	285
Cost of product sold	1,340	49
Royalty expense	418	96
Research and development	4,808	997
Selling, general and administrative	11,136	15,123
Total operating expenses	17,702	16,265
Loss from discontinued operations	(12,696)	(15,980)
Disposal Group, Including Discontinued Operation, Balance Sheet Disclosures [Abstract]
Trade accounts receivable	3,046		2,799
Inventory	787		1,995
Prepaid expenses	1,700		1,767
Other current assets	1,103		635
Total current assets of discontinued operations	6,636		7,196
Other assets	3,405		2,673
Total assets of discontinued operations	10,041		9,869
Accounts payable	4,786		3,781
Accrued expenses	9,983		9,470
Accrued compensation	1,747		1,933
Deferred revenue	4,881		7,123
Total current liabilities of discontinued operations	21,397		22,307
Total liabilities of discontinued operations	$ 21,397		$ 22,307